These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16713900)

  • 21. Targeting disease, not disease targets: Innovative approaches in tackling neurodegenerative disorders.
    Griffioen G
    IDrugs; 2007 Apr; 10(4):259-63. PubMed ID: 17390249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rational approaches to natural-product-based drug design.
    Haustedt LO; Mang C; Siems K; Schiewe H
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):445-62. PubMed ID: 16889228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mass spectrometric techniques for label-free high-throughput screening in drug discovery.
    Roddy TP; Horvath CR; Stout SJ; Kenney KL; Ho PI; Zhang JH; Vickers C; Kaushik V; Hubbard B; Wang YK
    Anal Chem; 2007 Nov; 79(21):8207-13. PubMed ID: 17902631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based approaches to antibiotic drug discovery.
    Nicola G; Abagyan R
    Curr Protoc Microbiol; 2009 Feb; Chapter 17():Unit17.2. PubMed ID: 19235149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind".
    Snowden M; Green DV
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):553-8. PubMed ID: 18600571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hit finding: towards 'smarter' approaches.
    Langer T; Hoffmann R; Bryant S; Lesur B
    Curr Opin Pharmacol; 2009 Oct; 9(5):589-93. PubMed ID: 19576852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved lead-finding for kinase targets using high-throughput docking.
    McInnes C
    Curr Opin Drug Discov Devel; 2006 May; 9(3):339-47. PubMed ID: 16729730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomic methods for drug target discovery.
    Sleno L; Emili A
    Curr Opin Chem Biol; 2008 Feb; 12(1):46-54. PubMed ID: 18282485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors.
    Chen J; Zhang Z; Stebbins JL; Zhang X; Hoffman R; Moore A; Pellecchia M
    ACS Chem Biol; 2007 May; 2(5):329-36. PubMed ID: 17465519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method.
    Castronovo V; Kischel P; Guillonneau F; de Leval L; Deféchereux T; De Pauw E; Neri D; Waltregny D
    Proteomics; 2007 Apr; 7(8):1188-96. PubMed ID: 17372937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovering potassium channel blockers from synthetic compound database by using structure-based virtual screening in conjunction with electrophysiological assay.
    Liu H; Gao ZB; Yao Z; Zheng S; Li Y; Zhu W; Tan X; Luo X; Shen J; Chen K; Hu GY; Jiang H
    J Med Chem; 2007 Jan; 50(1):83-93. PubMed ID: 17201412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A kinase-focused compound collection: compilation and screening strategy.
    Sun D; Chuaqui C; Deng Z; Bowes S; Chin D; Singh J; Cullen P; Hankins G; Lee WC; Donnelly J; Friedman J; Josiah S
    Chem Biol Drug Des; 2006 Jun; 67(6):385-94. PubMed ID: 16882313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probing cellular complexity with proteomics.
    Blackstock W; Rowley A
    Curr Opin Mol Ther; 1999 Dec; 1(6):702-11. PubMed ID: 19629867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
    Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
    ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemical proteomics-based drug design: target and antitarget fishing with a catechol-rhodanine privileged scaffold for NAD(P)(H) binding proteins.
    Ge X; Wakim B; Sem DS
    J Med Chem; 2008 Aug; 51(15):4571-80. PubMed ID: 18616236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of bioisosteric groups in lead optimization.
    Olesen PH
    Curr Opin Drug Discov Devel; 2001 Jul; 4(4):471-8. PubMed ID: 11727312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Focusing in on structural genomics: the University of Queensland structural biology pipeline.
    Puri M; Robin G; Cowieson N; Forwood JK; Listwan P; Hu SH; Guncar G; Huber T; Kellie S; Hume DA; Kobe B; Martin JL
    Biomol Eng; 2006 Dec; 23(6):281-9. PubMed ID: 17097918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel drug discovery and molecular biological methods, via DNA, RNA and protein changes using structure-function transitions: Transitional structural chemogenomics, transitional structural chemoproteomics and novel multi-stranded nucleic acid microarray.
    Gagna CE; Lambert WC
    Med Hypotheses; 2006; 67(5):1099-114. PubMed ID: 16828979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Network pharmacology: the next paradigm in drug discovery.
    Hopkins AL
    Nat Chem Biol; 2008 Nov; 4(11):682-90. PubMed ID: 18936753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The target discovery process.
    Egner U; Krätzschmar J; Kreft B; Pohlenz HD; Schneider M
    Chembiochem; 2005 Mar; 6(3):468-79. PubMed ID: 15742383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.